Differential interleukin 12 responsiveness for interferon γ production in advanced stages of cancer patients correlates with performance status

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2425-2432

  Uno, Kazuko ^a   Setoguchi, Junko ^a   Tanigawa, Mari ^a   Kishi, Atsuko ^a   Ogawa, Makoto ^b   Saotome, Hideo ^c   Fujiwara, Hiromi ^b   Kishida, Tsunataro ^a  

^a Louis Pasteur Center for Medical Research   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0031723917     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Trinchieri, G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood, 84: 4008-4027, 1994.
2. Brunda, M. J. Interleukin-12. J. Leukoc. Biol., 55: 280-288, 1994.
3. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med., 170: 827-845, 1989.
4. Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y. C., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L., Truitt, T., Chizzonite, R., and Gately, M. K. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 87: 6808-6812, 1990.
5. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Herrmann, S. H., and Ritz, J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med., 175: 779-788, 1992.
6. Gately, M. K., Desai, B. B., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., Podlaski, F. J., Familletti, P. C., Sinigaglia, F., Chizzonite, R., Gubler, U., and Stern, A. S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol., 147: 874-882, 1991.
7. Perussia, B., Chan, S. H., D'Andrea, A., Tsuji, K., Santoli, D., Pospisil, M., Young, D., Wolf, S. F., and Trinchieri, G. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ+ T lymphocytes, and NK cells. J. Immunol., 149: 3495-3502, 1992.
8. Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospisil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., and Trinchieri, G. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med., 173: 869-879, 1991.
9. Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G., and Romagnani, S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med., 177: 1199-1204, 1993.
10. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
11. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
12. Zou, J. P., Yamamoto, N., Fujii, T., Takenaka, H., Kobayashi, M., Herrmann, S. H., Wolf, S. F., Fujiwara, H., and Hamaoka, T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol., 7: 1135-1145, 1995.
13. Mu, J., Zou, J. P., Yamamoto, N., Tsutsui, T., Tai, X. G., Kobayashi, M., Herrmann, S., Fujiwara, H., and Hamaoka.,T. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55: 4404-4408, 1995.
14. Fujiwara, H., Zou, J. P., Herrmann, S., and Hamaoka, T. A sequence of cellular and molecular events involved in IL-12-induced tumor regression. Res. Immunol., 146: 638-644, 1995.
15. Fujiwara, H., Clark, S. C., and Hamaoka, T. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann. N. Y. Acad. Sci., 795: 294-309, 1996.
16. Ogawa, M., Tsutsu, T., Zou, J. P., Mu, J., Wijesuriya, R., Yu, W. G., Herrmann, S., Kubo, T., Fujiwara, H., and Hamaoka, T. Enhanced induction of VLA-4/LFA-1-dependent T-cell migration to tumor sites following administration of IL-12. Cancer Res., 57: 2216-2222, 1997.
17. Yu, W. G., Ogawa, M., Mu, J., Umehara, K., Tsujimura, T., Fujiwara, H., and Hamaoka, T. IL-12-induced tumor regression correlates with in situ activity of IFN-γ produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J. Leukoc. Biol., 62: 450-457, 1997.
18. Brunda, M. J., Luistro, L., Hendrzak, J. A., Fountoulakis, M., Garotta, G., and Gately, M. K. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. Emphas. Tumor Immunol., 17: 71-77, 1995.
19. Fujiwara, H., and Hamaoka, T. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol. Res., 14: 271-291, 1995.
20. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., and Sherman, M. L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 3: 409-417, 1997.
21. Uno, K., Nakano, K., Maruo, N., Onodera, H., Mata, H., Kurosu, I., Akatani, K., Ikegami, N., Kishi, A., Yasuda, Y., Tanaka, K., Setoguchi, J., Kondo, M., Muramtsu, S., and Kishida, T. Determination of interferon-α-producing capacity in whole blood cultures from patients with various diseases and from healthy persons. J. Interferon Cytokine Res., 16: 911-918, 1996.
22. American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd ed. Philadelphia: J. B. Lippincott Co., 1988.
23. Yamamoto, N., Zou, J. P., Li, X. F., Takenaka, H., Noda, S., Fujii, T., Ono, S., Kobayashi, Y., Mukaida, N., Matsushima, K., Fujiwara, H., and Hamaoka, T. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J. Immunol., 154: 2281-2290, 1995.
24. Tracey, K. J., and Cerami, A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol., 9: 317-343, 1993.
25. Collart, M. A., Belin, D., Vassalli, J. D., de Kossodo, S., and Vassalli, P. γ Interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J. Exp. Med., 164: 2113-2118, 1986.
26. Karnofsky, D. A., and Burchenal, J. H. The clinical evaluation of chemotherapeutic agents in cancer. Symposium, Microbiology Section, N. Y. Acad. Med., N. Y., 1948. New York: Columbia Univ. Press, 191-205, 1949.
27. Stanley, K. E. Prognostic factors for survival in patients with inoperable lung cancer. J. Natl. Cancer Inst., 65: 25-32, 1980.
28. Berry, W. R., Laazlo, J., Cox, E., Walker, A., and Paulson, D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer (Phila.), 44: 763-775, 1979.
29. Maldazys, J. D., and deKernion, J. B. Prognostic factors in metastatic renal carcinoma. J. Urol., 136: 376-379, 1986.
30. Li, X. F., Takiuchi, H., Zou, J. P., Katagiri, T., Yamamoto, N., Nagata, T., Ono, S., Fujiwara, H., and Hamaoka, T. Transforming growth factor-β (TGF-β)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-β and a progressive increase in TGF-β susceptibility of anti-tumor CD4+ T cell function. Jpn. J. Cancer Res., 84: 315-325, 1993.
31. Shirai, Y., Kawata, S., Tamura, S., Ito, N., Tsushima, H., Takaishi, K., Kiso, S., and Matsuzawa, Y. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer (Phila.), 73: 2275-2279, 1994.
32. Utsumi, K., Takai, Y., Tada, T., Ohzeki, S., Fujiwara, H., and Hamaoka, T. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J. Immunol., 145: 397-403, 1990.
33. Tomura, M., Nakatani, I., Murachi, M., Tai, X-G., Toyooka, K., and Fujiwara, H. Suppression of allograft responses induced by IL-6 which selectively modulates IFN-γ but not IL-2 production. Transplantation (Baltimore), 64: 757-763, 1997.
34. Blay, J. Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., Moskovtchenko, J. F., Philip, T., and Favrot, M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52: 3317-3322, 1992.
35. Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., and O'Garra, A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol., 146: 3444-3451. 1991.
36. Chang-you, W., Warrier, R. R., Wang, X., Presky, D. H., and Gately, M. K. Regulation of interleukin-12 receptor β1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur. J. Immunol., 27: 147-154, 1997.